Ironwood Financial llc Reduces Stock Holdings in Cencora, Inc. (NYSE:COR)

Ironwood Financial llc lowered its holdings in shares of Cencora, Inc. (NYSE:COR) by 0.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,891 shares of the company’s stock after selling 88 shares during the quarter. Ironwood Financial llc’s holdings in Cencora were worth $2,672,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in COR. Ieq Capital LLC raised its stake in Cencora by 8.7% during the 2nd quarter. Ieq Capital LLC now owns 9,613 shares of the company’s stock worth $2,166,000 after acquiring an additional 768 shares during the period. Benjamin F. Edwards & Company Inc. raised its position in shares of Cencora by 26.3% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,809 shares of the company’s stock valued at $1,759,000 after purchasing an additional 1,626 shares during the period. Bridges Investment Management Inc. purchased a new position in shares of Cencora during the 2nd quarter valued at $318,000. AE Wealth Management LLC boosted its holdings in Cencora by 2.5% in the 2nd quarter. AE Wealth Management LLC now owns 18,826 shares of the company’s stock worth $4,242,000 after buying an additional 468 shares during the period. Finally, Sei Investments Co. increased its stake in Cencora by 2.5% in the 2nd quarter. Sei Investments Co. now owns 275,154 shares of the company’s stock worth $61,994,000 after buying an additional 6,626 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Trading Up 0.5 %

Shares of COR stock opened at $242.11 on Monday. The company has a market cap of $46.80 billion, a PE ratio of 32.24, a price-to-earnings-growth ratio of 1.48 and a beta of 0.49. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $253.27. The stock’s 50 day simple moving average is $237.52 and its two-hundred day simple moving average is $234.01. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.91%. Cencora’s dividend payout ratio (DPR) is currently 29.29%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Mizuho assumed coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective on the stock. Leerink Partners dropped their price target on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Robert W. Baird lifted their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Barclays raised their target price on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Finally, Evercore ISI boosted their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 7.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the transaction, the executive vice president now owns 20,329 shares in the company, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 94,696 shares of company stock valued at $22,862,734 over the last three months. 15.80% of the stock is owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.